Study wrapper · #911
Phase III Open-Label, Randomized Clinical Trial of Epidermal Growth Factor and Growth Hormone Releasing Hexapeptide in Acute Ischemic Stroke.
Hernández-Bernal F, Subirós-Martínez N, Gutiérrez-Ronquillo JH, et al. Journal of clinical neuroscience. 2026.
DOI: 10.1016/j.jocn.2026.112195PubMed: 42462342
Editor's note
This trial studied GHRP-6 in combination with epidermal growth factor, so its effects cannot be isolated to the peptide alone. The study missed its primary endpoint, with benefit seen only in a small severe-stroke subgroup and an open-label design that limits confidence. A genuine but preliminary signal warranting further study.
Plain-language abstract
In this phase III open-label trial, combined epidermal growth factor and GHRP-6 for acute ischemic stroke did not improve overall disability at six months, though a pre-specified severe-stroke subgroup showed reduced disability and mortality.
Related coverage
Weak / none
EGF and GHRP6 Co-Administration Attenuates Cognitive Decline in Preclinical Models: Behavioral and Molecular Evidences.
Neurotoxicity researchn=——2026
Weak / none
A discovery-based proteomic approach of epidermal growth factor and growth hormone-releasing peptide-6 in a model of acute ischemic stroke.
Pharmacological reports : PRn=——2026
Weak / none
Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation.
Pharmaceuticals (Basel, Switzerland)n=——2026